239 related articles for article (PubMed ID: 24190964)
21. Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer.
Lawrie TA; Rabbie R; Thoma C; Morrison J
Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD010482. PubMed ID: 24142521
[TBL] [Abstract][Full Text] [Related]
22. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
Thigpen T; Vance R; Puneky L; Khansur T
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
[TBL] [Abstract][Full Text] [Related]
23. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
[TBL] [Abstract][Full Text] [Related]
24. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
Mirza MR; Åvall Lundqvist E; Birrer MJ; dePont Christensen R; Nyvang GB; Malander S; Anttila M; Werner TL; Lund B; Lindahl G; Hietanen S; Peen U; Dimoula M; Roed H; Ør Knudsen A; Staff S; Krog Vistisen A; Bjørge L; Mäenpää JU;
Lancet Oncol; 2019 Oct; 20(10):1409-1419. PubMed ID: 31474354
[TBL] [Abstract][Full Text] [Related]
25. Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer.
Pfisterer J; Vergote I; Du Bois A; Eisenhauer E; ; ;
Int J Gynecol Cancer; 2005; 15 Suppl 1():36-41. PubMed ID: 15839957
[TBL] [Abstract][Full Text] [Related]
26. Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience.
Dizon DS; Dupont J; Anderson S; Sabbatini P; Hummer A; Aghajanian C; Spriggs D
Gynecol Oncol; 2003 Dec; 91(3):584-90. PubMed ID: 14675681
[TBL] [Abstract][Full Text] [Related]
27. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
Holloway RW; Mehta RS; Finkler NJ; Li KT; McLaren CE; Parker RJ; Fruehauf JP
Gynecol Oncol; 2002 Oct; 87(1):8-16. PubMed ID: 12468336
[TBL] [Abstract][Full Text] [Related]
28. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.
Ledermann JA; Embleton AC; Raja F; Perren TJ; Jayson GC; Rustin GJS; Kaye SB; Hirte H; Eisenhauer E; Vaughan M; Friedlander M; González-Martín A; Stark D; Clark E; Farrelly L; Swart AM; Cook A; Kaplan RS; Parmar MKB;
Lancet; 2016 Mar; 387(10023):1066-1074. PubMed ID: 27025186
[TBL] [Abstract][Full Text] [Related]
29. Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data.
Rossi A; Chiodini P; Sun JM; O'Brien ME; von Plessen C; Barata F; Park K; Popat S; Bergman B; Parente B; Gallo C; Gridelli C; Perrone F; Di Maio M
Lancet Oncol; 2014 Oct; 15(11):1254-62. PubMed ID: 25232001
[TBL] [Abstract][Full Text] [Related]
30. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR).
Sehouli J; Chekerov R; Reinthaller A; Richter R; Gonzalez-Martin A; Harter P; Woopen H; Petru E; Hanker LC; Keil E; Wimberger P; Klare P; Kurzeder C; Hilpert F; Belau AK; Zeimet A; Bover-Barcelo I; Canzler U; Mahner S; Meier W
Ann Oncol; 2016 Dec; 27(12):2236-2241. PubMed ID: 27789470
[TBL] [Abstract][Full Text] [Related]
31. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
32. Effect of platinum sensitivity on the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancer.
Costales AB; Chambers L; Chichura A; Rose PG; Mahdi H; Michener CM; Yao M; Debernardo R
J Gynecol Obstet Hum Reprod; 2021 May; 50(5):101844. PubMed ID: 32590110
[TBL] [Abstract][Full Text] [Related]
33. Management of platinum-sensitive relapsed ovarian cancer, with particular reference to the International Collaboration in Ovarian Neoplasm-4/Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer-2.2 trial.
Kaye SB
Int J Gynecol Cancer; 2005; 15 Suppl 1():31-5. PubMed ID: 15839956
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.
Winter-Roach BA; Kitchener HC; Dickinson HO
Cochrane Database Syst Rev; 2009 Jan; (1):CD004706. PubMed ID: 19160239
[TBL] [Abstract][Full Text] [Related]
35. Chemotherapy for advanced gastric cancer.
Wagner AD; Syn NL; Moehler M; Grothe W; Yong WP; Tai BC; Ho J; Unverzagt S
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD004064. PubMed ID: 28850174
[TBL] [Abstract][Full Text] [Related]
36. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Pujade-Lauraine E; Hilpert F; Weber B; Reuss A; Poveda A; Kristensen G; Sorio R; Vergote I; Witteveen P; Bamias A; Pereira D; Wimberger P; Oaknin A; Mirza MR; Follana P; Bollag D; Ray-Coquard I
J Clin Oncol; 2014 May; 32(13):1302-8. PubMed ID: 24637997
[TBL] [Abstract][Full Text] [Related]
37. Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer.
Herzog TJ; Pignata S; Ghamande SA; Rubio MJ; Fujiwara K; Vulsteke C; Armstrong DK; Sehouli J; Coleman RL; Gabra H; Scambia G; Monk BJ; Arranz JA; Ushijima K; Hanna R; Zamagni C; Wenham RM; González-Martín A; Slomovitz B; Jia Y; Ramsay L; Tewari KS; Weil SC; Vergote IB
Gynecol Oncol; 2023 Mar; 170():300-308. PubMed ID: 36758420
[TBL] [Abstract][Full Text] [Related]
38. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
39. A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14).
Cognetti F; Bagnato A; Colombo N; Savarese A; Scambia G; Sehouli J; Wimberger P; Sorio R; Harter P; Mari E; McIntosh S; Nathan F; Pemberton K; Baumann K
Gynecol Oncol; 2013 Jul; 130(1):31-7. PubMed ID: 23234805
[TBL] [Abstract][Full Text] [Related]
40. A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse.
Vergote I; Armstrong D; Scambia G; Teneriello M; Sehouli J; Schweizer C; Weil SC; Bamias A; Fujiwara K; Ochiai K; Poole C; Gorbunova V; Wang W; O'Shannessy D; Herzog TJ
J Clin Oncol; 2016 Jul; 34(19):2271-8. PubMed ID: 27001568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
